What was Gold Royalty Corp (GROY)’s performance in the last session?

While Gold Royalty Corp has overperformed by 2.71%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GROY rose by 87.60%, with highs and lows ranging from $2.49 to $1.16, whereas the simple moving average jumped by 53.52% in the last 200 days.

On June 11, 2025, Canaccord Genuity started tracking Gold Royalty Corp (AMEX: GROY) recommending Buy. A report published by Raymond James on June 03, 2024, Upgraded its rating to ‘Outperform’ for GROY. Scotiabank Initiated an Sector Outperform rating on June 29, 2023, and assigned a price target of $3. National Bank Financial initiated its ‘Outperform’ rating for GROY, as published in its report on June 08, 2023. Raymond James’s report from July 25, 2022 suggests a price prediction of $3.75 for GROY shares, giving the stock a ‘Mkt Perform’ rating. BMO Capital Markets also rated the stock as ‘Market Perform’.

Analysis of Gold Royalty Corp (GROY)

Further, the quarter-over-quarter increase in sales is 8.43%, showing a positive trend in the upcoming months.

In order to gain a clear picture of Gold Royalty Corp’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -0.60% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.41, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

An average volume of 1.97M can be a very valuable indicator of volatility for GROY stock. On a monthly basis, the volatility of the stock is set at 5.37%, whereas on a weekly basis, it is put at 4.38%, with a gain of 0.44% over the past seven days. Furthermore, long-term investors anticipate a median target price of $3.30, showing growth from the present price of $2.27, which can serve as yet another indication of whether GROY is worth investing in or should be passed over.

How Do You Analyze Gold Royalty Corp Shares?

In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 16.92%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 14.09% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

GROY shares are owned by institutional investors to the tune of 14.09% at present.

Hot this week

RH (RH)’s results reveal risk

While RH has overperformed by 0.63%, investors are advised...

Was there any good news for NewAmsterdam Pharma Company NV (NAMS) stock in the last session?

While NewAmsterdam Pharma Company NV has overperformed by 2.88%,...

It would be worthwhile to take a closer look at Icecure Medical Ltd (ICCM)

While Icecure Medical Ltd has overperformed by 9.36%, investors...

The Neumora Therapeutics Inc (NMRA) had a good session last reading, didn’t it?

While Neumora Therapeutics Inc has overperformed by 0.71%, investors...

How should investors view Abeona Therapeutics Inc (ABEO)?

While Abeona Therapeutics Inc has overperformed by 1.57%, investors...

Topics

RH (RH)’s results reveal risk

While RH has overperformed by 0.63%, investors are advised...

Was there any good news for NewAmsterdam Pharma Company NV (NAMS) stock in the last session?

While NewAmsterdam Pharma Company NV has overperformed by 2.88%,...

It would be worthwhile to take a closer look at Icecure Medical Ltd (ICCM)

While Icecure Medical Ltd has overperformed by 9.36%, investors...

The Neumora Therapeutics Inc (NMRA) had a good session last reading, didn’t it?

While Neumora Therapeutics Inc has overperformed by 0.71%, investors...

How should investors view Abeona Therapeutics Inc (ABEO)?

While Abeona Therapeutics Inc has overperformed by 1.57%, investors...

Have you been able to find a good deal on Applovin Corp’s shares?

While Applovin Corp has underperformed by -0.07%, investors are...

A closer look at Tronox Holdings plc (TROX) is warranted

While Tronox Holdings plc has overperformed by 8.22%, investors...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.